THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER-Reference-Cited by-同舟云学术

THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER

Published:2001-05 Issue:5 Volume:165 Page:1585-1589
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

TOMERA KEVIN¹,GLEASON DONALD¹,GITTELMAN MARC¹,MOSELEY WILLIAM¹,ZINNER NORMAN¹,MURDOCH MYRON¹,MENON MANI¹,CAMPION MARILYN¹,GARNICK MARC B.¹,

Affiliation:

1. From the Alaska Clinical Research Center, Anchorage, Alaska, Advanced Clinical Therapeutics, Tucson, Arizona, South Florida Medical Research, Aventura, Florida, San Diego Uro-Research, San Diego and Western Clinical Research, Inc., Torrance, California, 206 Research Associates, Greenbelt, Maryland, Henry Ford Hospital, Detroit, Michigan, and Praecis Pharmaceuticals Inc., Cambridge, Massachusetts

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference9 articles.

1. Studies on prostate cancer. I. The effect of castration, estrogen and of androgen injections on serum phosphatase in metastatic carcinoma of the prostate;Huggins;Recent Results Cancer Res,1941

2. Leuprolide versus diethylstilbesterol for metastatic prostate cancer;The Leuprolide Study Group;N Engl J Med,1984

3. Prevention of the transient adverse effects of gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of antiandrogen (nilutamide);Kuhn;N Engl J Med,1989

4. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate;Schutze;J Urol,1990

5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate;Thompson;J Urol,1990

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiological and pharmacological overview of the gonadotropin releasing hormone;Biochemical Pharmacology;2023-06

2. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021;Journal of Hematology & Oncology;2022-10-08

3. Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape;Frontiers in Pharmacology;2022-08-30

4. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27

5. Advances with androgen deprivation therapy for prostate cancer;Expert Opinion on Pharmacotherapy;2022-02-02